Abstract
Introduction
Ischemic brain injury is one of the high risk factors for development of seizures; however, the underlying mechanisms responsible for provoked seizures remain to be determined. In general, it is believed that imbalanced excitatory (glutamate) and inhibitory (GABA) synaptic neurotransmissions coupled with altered functions of ion channels play a major role in regulating post-ischemic seizures [1] [2] [3] [4] .
It has been reported that the two main subtypes of GABA transport (GAT) responsible for the regulation of extracellular GABA levels in the central nervous system are GAT-1 and GAT-3 [5, 6] . Throughout the brain these transporters are widely expressed in neuronal cell (mainly GAT-1) and glial cells (mainly GAT-3), and published work has shown the role played by GATs in regulating GABAa receptor-mediated postsynaptic tonic and phasic inhibition in the cerebral cortex and hippocampus etc. [5, 6] . In light of the key role of GABAergic transmission within the brain regions related to epileptic activity [7, 8] , in this study, we examined expression of GAT-1 and GAT-3 in the parietal cortex, hippocampus and amygdala in a rat model of post-ischemic nonconvulsive seizure (NCS) evoked by the middle cerebral artery occlusion (MCAO).
Proinflammatory cytokines (PICs) such as IL-1β, IL-6 and TNF-α in plasma and cerebrospinal fluid and cells immunoreactive to those PICs in neuronal tissues are increased in patients during epileptic development [9, 10] . This is consistent with the role for PICs in engagement of the pathophysiology of epilepsy and/or brain damage following seizure. Moreover, a recent report has demonstrated that the protein levels of IL-1β, IL-6 and TNF-α in the parietal cortex, hippocampus and amygdala are significantly increased during epilepsy induced by cerebral injection of kainic acid [11] . Results of this study further suggest that upregulation of GAT-1 and GAT-3 is caused by epilepsy-increased IL-1β, IL-6 and TNF-α in those specific brain regions [11] . Thus, in the current report, we speculated that the increases of GAT-1 and GAT-3 would be accompanied with the greater levels of IL-1β, IL-6 and TNF-α in the parietal cortex, hippocampus and amygdala of NCS rats.
Nefiracetam (NEF) is one of pyrrolidone derivatives used to improve impaired cognitive functions often observed in patients with brain ischemic injury (i.e., stroke). It has recently been reported that NEF also attenuates seizure activities by increasing threshold of seizure evoked by amygdala-kindling and chemically induced seizures [12, 13] . Thus, NEF appears to be an important drug candidate to apply for both seizure prophylaxis and neuroprotection for patients suffering stroke who are more susceptible to developing post-ischemic seizures and cognitive dysfunctions. As a result, we examined the effects of NEF on the levels of IL-1β, IL-6 and TNF-α, and expression of GAT-1 and GAT-3 as well as the levels of GABA in the parietal cortex, hippocampus and amygdala of rats after induction of MCAO. We hypothesized that NEF attenuates MCAO-activated PICs and upregulated GABA transporters and thereby stabilizing GABA in the parietal cortex, hippocampus and amygdala. Through GABA mechanisms NEF is likely to improve NCS following MCAO.
Materials and Methods
All the animal procedures of this study and their care were conducted in conformity with the institutional guidelines that are in compliance with the Guideline for the Care and Use of laboratory Animals of the U.S. National Health Institute. Fifty-five male Sprague-Dawley rats (250-300 g) were used in our experiments and all animals were maintained under 12 hours light/dark-cycle with free access to food and water in a temperature-and humidity-controlled room.
The MCAO was performed to evoke NCS. Briefly, the rats were anesthetized with sodium pentobarbital (45 mg/kg body weight, i.p.) and then the right common carotid artery was exposed at the level of external and internal carotid artery bifurcation. The external carotid artery and its branches were closed and cut at the lingual and maxillary artery branches. A piece of 3-0 monofilament nylon suture was inserted into the internal carotid artery via the stump of the external carotid artery. The filament was advanced for ~20 mm into the anterior cerebral artery. During this surgical procedure, cortical cerebral blood flow (CBF) was continuously monitored with a laser-doppler flowmeter. Once a stable drop in blood flow signal was obtained ipsilateral to the occlusion, the filament was secured to the vessel by ligation. In general, the animals that show a decrease in CBF of >70% are considered ischemia and only those rats were included into data analysis in this study. In sham control rats, the surgical procedures were performed without arterial occlusion.
EEG recordings were performed and observed during 24 hours after induction of MCAO as described previously [14] . Briefly, four electrodes were implanted on the rat skull symmetrically through burr holes over bilateral frontal and parietal regions of the cortex (1 mm anterior and 4 mm posterior to bregma, 3.5 mm lateral to midline). A reference electrode was placed posterior to lambda over the transverse sinus. The electrodes were soldered to a multi-pin connector. A computerized EEG recording was obtained via a Grass polygraph amplifier and digitizing system (Grass Lab). The NCSs were detected via stainless steel electrodes implanted on the rat skull. The off-line EEG traces were analyzed using the NCS criteria defined previously [14] . The frequency of NCS was considered as the number of NCS events detected in each animal.
NEF (Sigma Co.) was dissolved in a saline solution at a final concentration of 15 mg/ml and given by intraperitoneal injection (i.p., 30mg/kg, twice). Note that the first dose was injected at the end of MACO surgery and the second one was injected 12 hours after the surgery. Control rats received the same volume of i.p. injection of saline. Rats' brains were removed 24 hours after the end of the MCAO surgery. Accordingly, the rats were divided into sham control group (n=15) and MCAO group (n=20) with saline injection and MCAO group with NEF injection (n=20).
The levels of IL-1β, IL-6 and TNF-α were determined using a two-site immunoenzymatic assay (ELISA, Promega Corp. Madison, WI) according to the provided description and modification. Briefly, polystyrene 96-well microtiter immunoplates were coated with affinity-purified polyclonal rabbit anti-IL-1β, anti-IL-6 and anti-TNF-α antibody. Parallel wells were coated with purified rabbit/mouse IgG for evaluation of nonspecific signal. After overnight incubation at room temperature and 2 hours of incubation with the coating buffer, plates were washed. The diluted samples and the each PIC standard solutions were distributed in each plate and left at room temperature overnight. The plates were washed and incubated with anti-IL-1β, anti-IL-6 and anti-TNF-α galactosidase per well. Then, the plates were washed and incubated with substrate solution. After an incubation of 2 hours at 37°C, the optical density was measured using an ELISA reader. In the similar way, GABA levels were determined by the ELISA methods (LDN Diagnostics, Inc. Colorado Spring, CO).
To examine expression of GAT-1 and GAT-3, the brain tissues were processed using a standard western blot procedure. Briefly, total protein was extracted by homogenizing samples of the parietal cortex, hippocampus and amygdala in ice-cold buffer. The buffer solution contains 25mM Tris·HCl (pH 7.6), 150 mM NaCl, 1% Nonidet (N) P-40, 1% sodium deoxycholate, and 0.1% sodium dodecyl sulfate (SDS) with protease inhibitor cocktail kit (Sigma-Aldrich, St. Louis, MO). The lysates were centrifuged and the supernatants were collected for measurements of protein concentrations. Protein concentrations of the samples were determined using the bicinchoninic acid assay reagent kit (Pierce Biotechnology, Rockford, IL) with bovine serum albumin as standard. After being denatured in buffer, the supernatant samples containing 20 μg of protein were loaded onto 4-20% Mini-PROTEAN TGX gels and electrically transferred to a polyvinylidene fluoride membrane. The membrane was blocked in 5% nonfat milk and was incubated overnight with primary antibodies [mouse anti-GAT-3 (sc-376001) 1:200/rabbit anti-GAT-1 (sc-135679) at 1:200, Santa Cruz products]. Next, the membranes were washed and incubated with an alkaline phosphatase conjugated anti-mouse/ant-rabbit secondary antibody (1:1000). The immunoreactive proteins were detected by enhanced chemiluminescence. The bands recognized by the primary antibody were visualized by exposure of the membrane onto an x-ray film. The membrane was stripped and incubated with mouse anti-β-actin to show equal loading of the protein. Then, the film was scanned and the optical density of GAT-1/GAT-3 and β-actin bands was analyzed using the Scion Image software.
All data were presented as mean ± standard error (SEM). One-way repeated-measures analysis of variance (ANOVA) was employed for comparison, followed by Tukey's post hoc test as appropriate. All statistical analyses were performed by using SPSS for Windows (version 13, SPSS). For all analyses, statistical significance was set at P < 0.05. Figure 1 shows that the levels of IL-1β, IL-6 and TNF-α were significantly increased in in the parietal cortex, hippocampus and amygdala of rats with MCAO (P<0.05 vs. control rats, n=15) as compared with control group. As MCAO rats received NEF injection (n=20), amplified IL-1β, IL-6 and TNF-α were significantly attenuated (P<0.05 vs. rats with vehicle injection, n=20; and P>0.05 vs .control rats, n=15). Figure 2 illustrates that expression of GAT-1 and GAT-3 in the parietal cortex, hippocampus and amygdala were significantly greater in MCAO rats (n=20, P<0.05 vs. control animals) than those in control rats (n=15). Also, NEF injection attenuated GAT-1 and GAT-3 expression (n=20, P<0.05 vs. MCAO animals with vehicle injection). However, there were not significant differences in GAT-1 and GAT-3 between control animals and MCAO animals that were injected with NEF. Figure 3 demonstrates that the levels of GABA were significantly less in the parietal cortex, hippocampus and amygdala of rats with MCAO (n=20, P<0.05 vs. control rats, n=15) as compared with control group. As NEF was given to MCAO rats (n=20), GABA was significantly improved (P<0.05 vs. rats with vehicle injection). Insignificant difference was observed in GABA levels between control animals and MCAO animals with NEF injection (P>0.05 vs. control rats, n=15).
Results
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There was no NCS observed in control rats (n=15). Rats appeared to have NCS following MCAO. Figure 4 further shows that injection of NEF significantly decreased the number of NCS. MCAO led to a less number of NCS in rats with NEF treatment as compared with rats that received vehicle (P<0.05, NEF vs. vehicle in MCAO rats, n=20 in each group).
Discussion
In general, PICs have been reported to be engaged alterations of neuronal damage and electronic encephalography related to epileptic activity and significant increases in IL-1β, IL-6 and TNF-α in hippocampus were observed following induction of seizure [15] . Using a rat model of epilepsy, a recent study further demonstrated that the levels of IL-1β, IL-6 and TNF-α in the specific brain regions such as the parietal cortex, hippocampus and amygdala were increased during seizure [11] . Moreover, results of this prior study showed that GABA transporters, namely GAT-1 and GAT-3 are upregulated during seizure via receptor mechanisms of IL-1β and TNF-α [11] . Accordingly, we examined the effects of NCS evoked by MCAO on IL-1β, IL-6 and TNF-α activity as well as expression of GAT-1 and GAT-3 in those brain regions. We further if injection of NEF improved the levels of cytokines and GAT-1 and GAT-3 and resultant GABA. Our data provided the first evidence that systemic injection of NEF plays a role in reinstating impaired GABA in the parietal cortex, hippocampus and amygdala likely via attenuating enhancement of IL-1β, IL-6 and TNF-α as well as GAT-1 and GAT-3.
Elevated levels of PICs in the brain are associated with increased seizure vulnerability and seizure-related pathological changes such as neuronal death [16] [17] [18] , suggesting that inflammation has been implicated in epileptogenesis. In a rat model of epilepsy, neural injuries in the brain occur and this is accompanied by upregulation of PICs including IL-1β, IL-6 and TNF-α in glial cells [15, 19] . Furthermore, neuronal degeneration is observed likely due to increases of PICs [20, 21] . For example, IL-1β can increase seizure susceptibility in rat brains [22] . Intracerebral injection of a high dosage of IL-1β results in limbic seizures in wild type mice, but not in transgenic mice with deficient IL-1β receptors [23] . In addition, antiepileptic activity is observed after using thalidomide to decrease the levels of TNF-α [24] .
With respect to the role played by central IL-6 in regulating epileptic activity, it should be acknowledged that prior studies demonstrate that IL-6 can stimulate the synthesis of corticotrophin and glucocorticoids, and initiate an anti-inflammatory feedback loop, suggesting a neuroprotective role played by IL-6 [25, 26] . A recent study showed that blocking receptors of IL-1β, IL-6 and TNF-α had different effects on expression of GAT-1 and GAT-3 [11] . It was suggested that activation of IL-1β and TNF-α receptors, but not IL-6 receptor plays a role in regulating GAT-1 and GAT-3. It is assumed that this discrepancy is likely due to intracellular signaling mechanisms for PICs to play a role. A great deal of evidence has demonstrated that IL-1β and TNF-α play a role mainly via p38 MAPK, ERK and JNK signaling transduction pathways, but IL-6 plays a role via JAK-STAT pathways [27] [28] [29] . After activation of those signaling pathways, gene transcription occurs [30] [31] [32] . What different mechanisms by which those signaling transduction pathways are responsible for regulating expression of GAT-1 and GAT-3 via PIC receptors needs to be determined. Nevertheless, it is crucial to determine neural substrates to play a role in the initiation of neuronal excitability responsible for NCS.
GABA is the main inhibitory neurotransmitter in the central nerve system in control of neuronal excitability. After GABA release from presynaptic terminals, GATs play a key role in regulating a rapid removal of extracellular GABA [1, 3] , which thereby leads to ending of inhibitory synaptic transmission. Thus, this mechanism is also responsible for GABA spillover to neighboring synapses [1, 2] and GABA homeostasis and then excessive tonic activation of synaptic and extrasynaptic GABA receptors are prevented [1, 4] . In contrast, under certain pathological and physiological conditions the GATs functions are impaired and this is likely to result in the exaggerated GABA release [33, 34] . Results of our current study demonstrated that the levels of IL-1β, IL-6 and TNF-α were significantly increased in the specific brain regions such as parietal cortex, hippocampus and amygdala after induction of MCAO (Fig. 1) . Also, our data further showed that protein expression of both GAT1 and GAT3 were greater in those brain regions of MCAO-animals than them in those regions of control animals (Fig. 2) . Consistent with this line of results, our data demonstrated that GABA levels were lower in those specific regions of MCAO rats than them in control rats (Fig. 3) . Important findings from the current study are that injection of NEF attenuated increases in IL-1β, IL-6 and TNF-α as well as augmented GAT1 and GAT3 expression and thereby restored the levels of GABA in those brain regions (Fig. 1-3) . Moreover, NEF significantly decreased the number of NCS events following induction of MCAO (Fig. 4) .
Overall, our data suggest that MCAO amplifies the levels of IL-1β, IL-6 and TNF-α in in the parietal cortex, hippocampus and amygdala. Our data also suggest that MCAO leads to upregulation of GAT-1 and GAT-3 likely via stimulation of IL-1β and TNF-α receptors and downregulation of GABA. As a result, GABA-mediated inhibitory effects on neuronal activities in those specific brain regions are impaired and this is likely to cause neurological deficits induced by MCAO. Since GAT-1 is widely expressed in neuronal cells and GAT-3 is mainly present in glial cells throughout the brain [1, 5] , results of the current study suggest that PICs are likely to play a role in regulating a GABA inhibitory system in the neuronal and glial cells after induction of NCS. NEF plays a beneficial role in regulating NCS via GABA pathways following MCAO.
A few issues need to be acknowledged. First, data of our current study did not determine what cellular mechanism to drive cytokine expression. Second, we did not determine whether neuronal cells and/or glial cells secrete cytokines. In this study, we used ELISA method to examine the levels of cytokines in a quantitative manner and this provided us a better opportunity making comparison of cytokines among groups. In contrast, it should be noted that immunohistochemical method is a better method to examine localization of cytokines, which possibly identifies cytokine positive staining in neurons and/or glial cells. It is speculated that both neuronal cells and glial cells are likely engaged in increases of cytokines in the specific brain regions examined since MCAO leads to a global brain injuries.
Conclusion
We have provided evidence that cerebral ischemia induced-NCS and this amplifies the levels of IL-1β, IL-6 and TNF-α in the parietal cortex, hippocampus and amygdala. Ischemia further leads to upregulation of GABA transporter subtypes GAT-1 and GAT-3 thereby decreases the levels of GABA in those brain regions. These abnormalities are likely to contribute to the enhanced neuronal excitability in those brain regions of animals with NCS. Of note, systemic administration of NEF improves enhancement of cytokines as well as amplified GAT-1 and GAT-3 expression and restores impaired GABA. This further improves cerebral ischemia evoked-NCS. Our results may offer promising clues for the development of new therapeutic strategies for managing intractable symptoms observed in patients with epilepsy after cerebral ischemia.
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